Free Trial
→ Social Security’s trust fund runs short in 2032. Guess who controls Congress. (From Priority Gold) (Ad)tc pixel
NASDAQ:SRZN

Surrozen Q4 2025 Earnings Results & Report

Surrozen logo
$31.88 -0.76 (-2.33%)
Closing price 11/11/2026 04:00 PM Eastern
Extended Trading
$31.96 +0.08 (+0.24%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Surrozen missed analyst expectations on both earnings and revenue in its Q4 2025 results, released March 23, 2026. The company reported EPS of -$7.59 versus the -$1.2875 consensus estimate, while revenue of $528 thousand fell short of the $661 thousand estimate by $133 thousand.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Surrozen EPS Results

Actual EPS
-$7.59
Consensus EPS
-$1.2875
Beat/Miss
Missed by -$6.3025
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Surrozen Revenue Results

Actual Revenue
$528 thousand
Expected Revenue
$661 thousand
Beat/Miss
Missed by -$133.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Surrozen's Q4 2025 Press ReleasePress Release
(8-K)
Surrozen's Q4 2025 Annual reportAnnual report
(10-K)

Surrozen Q4 2025 Earnings FAQ

Surrozen (NASDAQ:SRZN) reported earnings of -$7.59 per share for Q4 2025, missing the consensus estimate of -$1.2875. The report was announced on Monday, March 23, 2026.

Surrozen reported revenue of $528 thousand for Q4 2025, against a consensus estimate of $661 thousand.

Surrozen Earnings Headlines

Cantor Fitzgerald Forecasts Strong Price Appreciation for Surrozen (NASDAQ:SRZN) Stock
November 12 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31193209
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
November 10 at 1:31 AM  |  marketscreener.comM
Social Security’s trust fund runs short in 2032. Guess who controls Congress.
Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. After that, only about 78% of scheduled benefits can be paid unless Congress acts. Higher taxes, smaller checks or more borrowing are all on the table. The morning after Democrats took Congress, gold jumped almost 3% and silver jumped 4%. If you count on Social Security for any part of your retirement, a backup plan matters before 2032.tc pixel
November 12 at 1:00 AM  |  Priority Gold (Ad)
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
November 9 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/09/3398957/0/en/surrozen-reports-third-quarter-2026-financial-results-and-provides-business-update.html
Surrozen: The Wnt Science Is Compelling, But The Stock Prices In Too Much Success
November 9 at 3:29 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4965128-surrozen-the-wnt-science-is-compelling-but-the-stock-prices-in-too-much-success
Surrozen to Present at Upcoming Healthcare Investor Conference
November 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/06/3397902/0/en/surrozen-to-present-at-upcoming-healthcare-investor-conference.html
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN) is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues. Its development programs have focused on potential treatments for diseases involving the liver, gastrointestinal system and other tissues where impaired regeneration contributes to disease.

Surrozen’s pipeline has included SZN-043, an investigational Wnt pathway agonist being developed for liver-related conditions, and SZN-1326, an investigational program aimed at gastrointestinal diseases such as ulcerative colitis. The company’s programs remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established.

View Surrozen Profile
Earnings Tools